Scopus Publications
- Neuronal injury biomarkers GFAP and neurofilament light chains (NfL) are associated with neurotoxicity and endothelial dysfunction in adult patients treated with antiCD19 CART cells
Eugenio Galli, Anna Modoni, Luca Battistini, Monica Rossi, Gisella Guerrera, et al.
Clinical and Experimental Medicine, 2026 - High Frequency of Germline ATM Variants in Familial Philadelphia-Negative Myeloproliferative Neoplasms
Francesco Ramundo, Tanja Malara, Luca Di Marino, Roberto Maggi, Silvia Betti, et al.
American Journal of Hematology, 2026 - Organ-specific local cytokine release syndrome after anti-CD19 CAR-T therapy with salivary gland involvement: a case report, literature review, and a diagnostic alert for tocilizumab-associated cervical swelling
Roberto Maggi, Enrico Federico Ricciuti, Eugenio Galli, Federica Sorà, Antonella Fiorita, et al.
Annals of Hematology, 2026 - Advanced deep learning enables prediction of allogeneic stem cell mobilization success
Asif Adil, Jingyu Xiang, Nicola Piccirillo, Hillary G. Harris, Simona Sica, et al.
Bone Marrow Transplantation, 2026 - Late outcomes after posttransplant cyclophosphamide–based GVHD prophylaxis in patients with AML: an ALWP-EBMT study
Eduardo Rodríguez-Arbolí, Allain-Thibeault Ferhat, Anna Maria Raiola, Linde Morsink, Didier Blaise, et al.
Blood Neoplasia, 2026 - The impact of daratumumab-containing induction on stem cell mobilization, collection and engraftment in newly diagnosed multiple myeloma: results of the prospective DILEMMA study
Caterina Giovanna Valentini, Claudio Pellegrino, Patrizia Chiusolo, Elena Rossi, Rossella Ladiana, et al.
Haematologica, 2026 - COMBINED NF1/SUZ12 HAPLOINSUFFICIENCY DRIVES ABERRANT ACTIVATION OF THE RAS SIGNALING CASCADE IN IMMATURE HOXA-POSITIVE T-ALL
Valentina Bardelli
Haematologica, 2026
Introduction. Deletions of the long arm of chromosome 17 (I-17q) in immature T-cell acute lymphoblastic leukemia (T-ALL) of adults encompass NF1 and SUZ12. NF1 encodes a negative regulator of the RAS pathway while SUZ12, a member of the PRC2 complex, is an epigenetic modulator that mediates the methylation of H3K27. Inactivation of NF1 and SUZ12 has been reported to synergistically enhance RAS/MAPK signaling in JMML and solid tumors (Zhang M, Nat Genet 2014; Caye A, Nat Genet 2015; de Raedt T, Nature 2014).Aim. To elucidate the biological and functional impact of NF1 and SUZ12 haploinsufficiency in T-ALL.Methods. The I-17q abnormality was detected in 39 out of 447 genomically characterized T-ALL cases (288 adults and 159 children) using a multimodal approach combining FISH, SNP array, and targeted custom NGS analyses. SUZ12 knock down (SUZ12-KD) in the PF382-Cas9 cell line, which harbors an NF1 loss-of-function mutation, was used to model concurrent NF1 and SUZ12 haploinsufficiency. Gene expression analysis was performed by Whole Transcriptome Expression array (WTEa) (Bardelli V, J Mol Diagn 2025) and qRT-PCR, while MAPK pathway activation was assessed by Western blot analysis of phosphorylated ERK (pERK).Results. I-17q correlated with NF1 and SUZ12 haploinsufficiency and was restricted to the leukemic clone, disappearing upon hematologic and cytogenetic remission. It was significantly linked to adulthood (Chi-square, p = 0.002) and an immature phenotype (p < 0.001), and was enriched in cases with high HOXA expression levels (present in >40% of I-17q–positive cases), which in 68% of cases were driven by known genomic alterations (3 HOXA, 3 NUP214, 2 MLLT10, 2 ZFP36L2, and 1 KMT2A). According to the immature phenotype, upregulation of IGFBP7, MN1, CD34, MEF2C, RUNX2, and BAALC, typically expressed in hematopoietic/progenitor cells, was observed. In addition, GSEA demonstrated enrichment of MAPK pathway signature. In vitro studies showed that the NF1-mutant PF382 cell line exhibited increased ERK phosphorylation after SUZ12 knockdown. Furthermore, enhanced ERK phosphorylation was observed in primary I-17q samples, supporting a cooperative role of NF1 and SUZ12 loss.Conclusion. I-17q marks immature T-ALL of adults with high levels of HOXA expression. Reflecting a model of concurrent NF1/SUZ12 loss observed in other human tumors, our data indicate that NF1 loss drives activation of the RAS/RAF/MEK/ERK pathway, which is further enhanced by SUZ12 haploinsufficiency, highlighting this signaling cascade as a potential therapeutic target. - A Modified-Delphi Consensus on the Management of Patients with FLT3-Mutated AML
Jacopo Olivieri, Emanuele Angelucci, Roberto Cairoli, Maria Paola Martelli, Massimo Martino, et al.
Cancers, 2026
Background/Objectives: The emergence of FLT3 inhibitors (FLT3i) has radically transformed the prognostic and therapeutic landscape for FLT3-mutated Acute Myeloid Leukemia, stimulating the need for comprehensive and structured clinical guidance. Methods: We aimed to develop evidence-based recommendations spanning the entire disease continuum of FLT3-mutated AML from leading Italian experts through a modified Delphi consensus process. Results: The panel achieved a high degree of agreement on specific interventions covering diagnostic testing, upfront FLT3i integration, role of allogeneic hematopoietic cell transplantation (allo-HSCT), Minimal Residual Disease (MRD) monitoring, and relapsed/refractory (R/R) strategies. Key recommendations mandate that analysis for both FLT3-ITD and FLT3-TKD mutations is required at diagnosis, with capillary electrophoresis or NGS as preferred methods. All fit patients with FLT3m-AML must receive intensive chemotherapy plus a FLT3i (midostaurin or quizartinib) and be evaluated for allo-HSCT. For unfit patients, the current standard of HMA + venetoclax is considered suboptimal, making the search for alternative strategies imperative. MRD monitoring using available molecular or flow cytometry markers is recommended to assess relapse risk and to optimize the allo-HSCT strategy. In the R/R setting, retesting the FLT3 status is mandatory, and gilteritinib is the standard treatment, serving as a bridge-to-transplant and for post-HSCT maintenance. Conclusions: The integration of FLT3i has shifted FLT3m-AML into a more favorable intermediate prognostic category, enhancing the role of curative strategies like allo-HSCT. This consensus paper provides a structured evidence-based comprehensive guide, translating complex data into clear actionable clinical recommendations that minimize practice variability and ultimately optimize management for this high-risk population. - Differences between Physicians’ and Nurses’ Perspectives in Defining Core Nursing-Sensitive Outcomes in Adult HSCT and CAR-T Therapy: An Interdisciplinary Italian Delphi Consensus
Marco Cioce, Simona Sica, Sarah Jayne Liptrott, Fabio Lamberti, Simona Calza, et al.
Bone Marrow Transplantation, 2026 - Immunomodulatory effect of dasatinib plus blinatumomab versus ponatinib plus blinatumomab in newly diagnosed Ph+ acute lymphoblastic leukemia
Michela Ansuinelli, Nadia Peragine, Maria Stefania De Propris, Maria Cristina Puzzolo, Mariangela Di Trani, et al.
Leukemia, 2026 - Vascular inflammation in patients undergoing anti-CD19 chimeric antigen receptor-T cells for haematologic malignancies: a call for cardiovascular surveillance
Massimiliano Camilli, Andrea Guarneri, Lucia Leccisotti, Federico Ballacci, Marcello Viscovo, et al.
European Heart Journal, 2026 - Unrelated donor transplantation for relapsed refractory aplastic anemia, with quadruple GvHD prophylaxis
Sabrina Giammarco, Andrea Bacigalupo, Nicola Mordini, Francesco Zallio, Irene Cavattoni, et al.
Bone Marrow Transplantation, 2026 - Donor selection in PTCy haploidentical transplant for acute lymphoblastic leukemia: a study from the ALWP of the EBMT
Jaime Sanz, Allain-Thibeault Ferhat, Anna Maria Raiola, Didier Blaise, Mutlu Arat, et al.
Bone Marrow Transplantation, 2026 - Real life use of ravulizumab in Italian patients with paroxysmal nocturnal hemoglobinuria: evidence from the REACTION observational study
Anna Paola Iori, Antonio De Vivo, Eros Di Bona, Giovanni Caocci, Francesca Fioritoni, et al.
Annals of Hematology, 2026 - Trends in GVHD Epidemiology, Prophylaxis and Management: The Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO) GVHD24 Study
Nicola Polverelli, Caterina Zerbi, Maria Grazia Benevento, Mattia Algeri, Alessandra Algarotti, et al.
American Journal of Hematology, 2026 - Validation of a New Scoring System for Treatment Failure in CML Patients on Tyrosine Kinase Inhibitors in a Real-World Setting
Andrea Mattozzi, Eugenio Galli, Francesco Autore, Ilaria Pansini, Patrizia Chiusolo, et al.
Mediterranean Journal of Hematology and Infectious Diseases, 2026 - Key Indications for Passive Immune Prophylaxis Against SARS-CoV-2 Infection in Malignant Hematological Disorders: An Analytic Hierarchy Process by an Ad Hoc Italian Expert Panel
Monia Marchetti, Giovanni Barosi, Francesco Passamonti, Marco Falcone, Emanuele Nicastri, et al.
Vaccines, 2026 - Outcomes of primary graft failure in acute myeloid leukemia patients following unrelated transplantation with post-transplant cyclophosphamide: a study from the ALWP/EBMT
Arnon Nagler, Jacques-Emmanuel Galimard, Sarah Kayser, Alexander Kulagin, Didier Blaise, et al.
Bone Marrow Transplantation, 2026 - Use of bone marrow cells is associated with improved outcomes when compared to peripheral blood stem cell after haplo-identical transplants with post transplant cyclophosphamide, a study from of the CTIWP-EBMT
Vanderson Rocha, Myriam Labopin, Anna Maria Raiola, Raynier Devillier, Stefania Bramanti, et al.
Bone Marrow Transplantation, 2026 - CD19 expression on bone marrow hematogones and blasts following anti-CD19 therapy in B-ALL: a descriptive single-center analysis
Gabriele Schiaffini, Giacomo Di Cesare, Elisabetta Metafuni, Elena Maiolo, Maria Assunta Limongiello, et al.
Leukemia and Lymphoma, 2026 - Venetoclax plus hypomethylating agents as first salvage therapy for myeloid malignancies relapsing after allogeneic HSCT
Patrizia Chiusolo, Michele Malagola, Fabio Giglio, Filippo Frioni, Carolina Secreto, et al.
Bone Marrow Transplantation, 2026 - Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint
Fausto Castagnetti, Massimo Breccia, Elisabetta Abruzzese, Renato Bassan, Gianni Binotto, et al.
Leukemia, 2026 - Adult Onset of Type 2 Familial Hemophagocytic Lymphohistiocytosis After SARS-CoV-2 Vaccination with an Unusual Neurological Onset: The Great Mimic
Flaminia Bellisario, Assunta Bianco, Francesco D’Alo’, Chiara Passarelli, Rosellina Russo, et al.
Diagnostics, 2025 - Bloodstream infection by Lactobacillus rhamnosus in a haematology patient: why metagenomics can make the difference
Cataldo Maria Mannavola, Flavio De Maio, John Marra, Barbara Fiori, Giulia Santarelli, et al.
Gut Pathogens, 2025 - Time to anti-cancer treatment resumption after SARS-CoV-2 infection in patients with active haematological diseases undergoing combined antiviral treatments
E Matteini, C Pinnetti, F Frondizi, E Rando, M Chiuchiarelli, et al.
Journal of Antimicrobial Chemotherapy, 2025
